A promising research direction for colorectal cancer immunotherapy : The regulatory mechanism of CCL5 in colorectal cancer
Copyright © 2022 Li, Lei, Sun, Zhang, Li, Chen, Kong, Chen, Bi, Luo, Wang, Li, Luo and Xu..
Colorectal cancer (CRC) is one of the leading causes of cancer death worldwide, with high morbidity and mortality rates worldwide. Therefore, there is an urgent need to develop more effective treatments for CRC patients. In recent years, there has been some success in the immunotherapy of tumors, and immunotherapy has been used in many solid tumors including CRC. To date, the clinical efficacy of immunotherapy for CRC is limited, so more effective immunotherapy methods need to be explored. In patients with CRC, the CC chemokine CCL5 plays a role in the development of CRC and the recruitment and activation of immune cells, suggesting that it has potential for immunotherapy. This review mainly introduces the latest advances in the study of CCL5 acting as a marker of CRC and related mechanisms of immunotherapy, as well as the latest understanding of how CCL5 is involved in the invasion and development of CRC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Frontiers in oncology - 12(2022) vom: 22., Seite 1020400 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Yuansen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CCL5 |
|---|
| Anmerkungen: |
Date Revised 18.11.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fonc.2022.1020400 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349004277 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349004277 | ||
| 003 | DE-627 | ||
| 005 | 20231226205549.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fonc.2022.1020400 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1163.xml |
| 035 | |a (DE-627)NLM349004277 | ||
| 035 | |a (NLM)36387070 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Yuansen |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A promising research direction for colorectal cancer immunotherapy |b The regulatory mechanism of CCL5 in colorectal cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.11.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022 Li, Lei, Sun, Zhang, Li, Chen, Kong, Chen, Bi, Luo, Wang, Li, Luo and Xu. | ||
| 520 | |a Colorectal cancer (CRC) is one of the leading causes of cancer death worldwide, with high morbidity and mortality rates worldwide. Therefore, there is an urgent need to develop more effective treatments for CRC patients. In recent years, there has been some success in the immunotherapy of tumors, and immunotherapy has been used in many solid tumors including CRC. To date, the clinical efficacy of immunotherapy for CRC is limited, so more effective immunotherapy methods need to be explored. In patients with CRC, the CC chemokine CCL5 plays a role in the development of CRC and the recruitment and activation of immune cells, suggesting that it has potential for immunotherapy. This review mainly introduces the latest advances in the study of CCL5 acting as a marker of CRC and related mechanisms of immunotherapy, as well as the latest understanding of how CCL5 is involved in the invasion and development of CRC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CCL5 | |
| 650 | 4 | |a chemokines | |
| 650 | 4 | |a colorectal cancer | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a the tumor microenvironment | |
| 700 | 1 | |a Lei, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Jiaxue |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wanfu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xiaogang |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Sijing |e verfasserin |4 aut | |
| 700 | 1 | |a Kong, Deshenyue |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Bi, Ke |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Xiao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Huayou |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in oncology |d 2011 |g 12(2022) vom: 22., Seite 1020400 |w (DE-627)NLM218189583 |x 2234-943X |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g day:22 |g pages:1020400 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fonc.2022.1020400 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |b 22 |h 1020400 | ||